Protocols

Compounding or selling retatrutide outside a registered clinical trial is both federally illegal and clinically unsafe in 2026. The FDA has explicitly stated that retatrutide cannot be legally compounded under either the 503A or 503B pathways. No reference standard exists for purity verification, and Eli Lilly has filed multiple lawsuits against companies selling the compound illicitly.

The FDA's Pharmacy Compounding Advisory Committee voted in favour of adding six peptides — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax — to the 503A bulk list in July 2026, overriding staff opposition. That vote is non-binding and changes nothing in current law. For four of the six, the FDA's own briefing documents found no human safety studies at all.

A 2025 PNAS study from Yale found that semaglutide recruits — rather than silences — AgRP hunger neurons in female mice, and that this recruitment is required for the drug's full weight-lowering effect. A parallel JCI study confirmed rapid AgRP inhibition at pharmacologic doses, revealing a context-dependent, bidirectional relationship between GLP-1 receptor agonists and hypothalamic hunger circuitry.

Neither BPC-157 nor TB-500 has completed a human randomised controlled trial for ulcerative colitis, wound healing, or pain as of 2026. FDA staff concluded the evidence was inadequate for all three indications. An advisory committee nonetheless voted 8-6 in favour of adding both to the 503A compounding list — a non-binding recommendation that has not yet changed legal compounding status.

As of 2026, the human dose-response record for BPC-157 consists of a Phase 1 tolerability study in two healthy adults, an unpublished Phase 2 enema trial in ulcerative colitis, and a small number of soft-tissue case series. No dose-response curve has been established in humans for any indication. FDA reviewers characterised the available data as sparse, short, and exploratory.

Administration route materially alters BPC-157's pharmacokinetic profile and, by extension, which tissue-injury types are most likely to respond. Two 2026 reviews — Mateescu in Pharmaceutics and Yuan in IJMS — establish that subcutaneous injection favours musculoskeletal targets, oral administration favours gastrointestinal mucosa, and intra-articular delivery is supported by a small human case series for joint pathology.

As of 2026, no completed randomised controlled trial has evaluated emideltide — the synthetic analogue of delta sleep-inducing peptide (DSIP) — in insomnia, narcolepsy, or opioid use disorder. The available human record consists of small uncontrolled Soviet-era infusion studies and one opioid withdrawal series. Regulators have explicitly cited this evidence gap as the central barrier to any compounding pathway.

No validated safe dose for BPC-157 in humans has been established as of 2026. The compound carries five categorised safety risk classes — oncological, immunogenic, cardiovascular, neurological, and drug-interaction — each grounded in preclinical mechanism rather than observed human adverse events. No completed human pharmacokinetic study exists, making rational dose selection impossible by current clinical standards.

TRIUMPH-1 Phase 3 data show retatrutide 12 mg achieving approximately 28% mean body-weight reduction at 80 weeks, exceeding semaglutide at approximately 15% and tirzepatide at approximately 22% in their respective pivotal trials. A 2025 network meta-analysis confirms the superiority signal. No direct head-to-head trial has yet reported results.

As of 2026, no completed randomised controlled trial has generated primary human safety data for BPC-157 in musculoskeletal recovery or gut repair. The available human record consists of intra-articular case series, one early-phase gastrointestinal pilot, and a registered but unpublished Phase 2 RCT. The July 2026 FDA PCAC review confirmed this gap as the central barrier to any approval pathway.

Tesamorelin, a stabilised GHRH analogue approved for HIV-associated lipodystrophy, has accumulated controlled human evidence for visceral fat reduction, liver fat attenuation, and modest lipid improvements in non-HIV populations. The strongest signals come from a 2019 RCT in non-HIV adults with abdominal obesity and a 2021 NAFLD trial. No regulatory approval exists outside the HIV indication as of 2026.

Phase 2 and TRIUMPH-1 Phase 3 data show retatrutide's cardiometabolic burden is manageable at 9 mg but clinically meaningful at 12 mg in patients with pre-existing cardiac risk. The glucagon receptor-mediated heart rate increase is the primary signal. No oral formulation exists. The 9 mg dose is the evidence-supported inflection point where efficacy is maximised without disproportionate cardiometabolic cost.